Case Report: Methadone Maintenance Dose of 1200 mg/day in an Ultra-rapid Metabolizer

REFERENCES

• Addiction Treatment Forum. (2000). MMT & beyond—The 100 mg/d methadone glass ceiling. Retrieved March 13, 2009 from http://www.atforum.com/SiteRoot/pages/current_pastissues/fall2000.shtml
   Google Scholar
• Addiction Treatment Forum. (2009). Methadone prescribing: What is the best dose of methadone? Retrieved March 11, 2009 from http://www.atforum.com/faqs/perscribing.php
   Google Scholar
• Adelson, M., Peles, E., Bodner, G., & Kreek, M.J. (2007). Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. Journal of Addictive Diseases, 26(1), 15–26.
   PubMed Web of Science ®Google Scholar
• Bell, J., Seres, V., Bowron, P., Lewis, J., & Batey, R. (1988). The use of serum methadone levels in patients receiving methadone maintenance. Clinical Pharmacology and Therapeutics, 43(6), 623–629.
   PubMed Web of Science ®Google Scholar
• Borg, L., Ho, A., Peters, J.E., & Kreek, M.J. (1995). Availability of reliable serum methadone determination for management of symptomatic patients. Journal of Addictive Diseases, 14(3), 83–96.
   PubMed Web of Science ®Google Scholar
• Caplehorn, J.R., Bell, J., Kleinbaum, D.G., & Gebski, V.J. (1993). Methadone dose and heroin use during maintenance treatment. Addiction, 88, 119–124.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment (CSAT). (2005). Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment Improvement Protocol (TIP)Series 43. DHHS Publication No. (SMA) 05–4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005. Retrieved on November 18, 2008 from http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.section.82907
   Google Scholar
• Charlier, C., Dessalles, M.C., & Plomteu, G. (2001). Methadone maintenance treatment: Is it possible to adapt the daily doses to the metabolic activity of the patient? Therapeutic Drug Monitoring, 23(1), 1–3.
   PubMed Web of Science ®Google Scholar
• Crettol, S., Deglon, J.J., Besson, J., Croquette-Krokar, M., Hummig, R., Gothuey, I., Monnat, M., & Eap, C. (2006). ABCB1 and Cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clinical Pharmacology & Therapeutics, 80, 668–681.
   PubMed Web of Science ®Google Scholar
• Craig, R.J. (1980). Effectiveness of low dose methadone maintenance for the treatment of inner city heroin addicts. International Journal of the Addictions, 15(5), 701–710.
   PubMed Web of Science ®Google Scholar
• de los Cobos, J.P., Sinol, N., Trujols, J., del Rio, E., Banuls, E., Luquero, El, Menoyo, A., Queralto, M., Baiget, M., Alvarez, E., and the Barcelona Group for Addiction Genetics. (2006). Drug and Alcohol Dependence, 89(2–3), 190–194.
   PubMedGoogle Scholar
• Cruciani, R.A., Sekine, R., Homel, P., Lussier, D., Yap, Y., Suzuki, Y., Schweitzer, P., Yancovitz, S.R., Lapin, J.A., Shaiova, L., Sheu, R.G., & Portenoy, R.K. (2005). Measurement of QTc in patients receiving chronic methadone therapy. Journal of Pain and Symptom Management in Patients Receiving Chronic Methadone Therapy, 29(4), 385–391.
   PubMed Web of Science ®Google Scholar
• Dole, V.P. (1970). Biochemistry of addiction. Annual Reviews in Biochemistry, 39, 821–840.
   PubMed Web of Science ®Google Scholar
• Dole, V.P. (1988). Implications of methadone maintenance for theories of narcotic addiction. JAMA: The Journal of the American Medical Association, 260(20), 3025–3029.
   PubMed Web of Science ®Google Scholar
• Dole, V.P. (1994). What have we learned from three decades of methadone maintenance treatment? Drug and Alcohol Review, 13, 3–4.
   PubMedGoogle Scholar
• Dole, V.P. & Nyswander, M.E. (1965). Medical treatment for diacetyl-morphine (heroin) addiction. JAMA: The Journal of the American Medical Association, 193, 80–84.
   Web of Science ®Google Scholar
• Dole, V.P. & Nyswander, M.E. (1967). Heroin addiction—A metabolic disease. Archives of Internal Medicine, 120, 19–24.
   PubMed Web of Science ®Google Scholar
• Dole, V.P., Nyswander, M.E., & Kreek, M.J. (1966). Narcotic blockade. Archives of Internal Medicine, 8, 304–309.
   Google Scholar
• Donny, E.C., Walsh, S.L., Bigelow, G.E., Eissenberg, T., & Stitzer, M.L. (2002). High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacolgy, 161, 202–212.
   PubMed Web of Science ®Google Scholar
• Dyer, K.R., Foster, D.J.R., White, J.M., Somogyi, A.A., Menelaou, A., & Bochner, F. (1999). Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 65(6), 685–694.
   PubMed Web of Science ®Google Scholar
• Eap, C.B., Buclin, T., & Baumann, P. (2002). Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clinical Pharmacokinetics, 41(14), 1153–1193.
   PubMed Web of Science ®Google Scholar
• Eap, C.B., Deglon, J.J., & Baumann, P. (1999). Pharmacokinetics and pharmacogenetics of methadone: Clinical relevance. Heroin Addiction & Related Clinical Problems, 1(1), 19–34.
   Google Scholar
• Ericson, N. (2001). Substance abuse: The nation's number one health problem. OJJDP Fact Sheet, May 2001, #17. Office of Juvenile Justice and Delinquency Prevention, U.S. Department of Justice.
   Google Scholar
• Farrell, M., Ward, J., Mattick, R., Hall, W., Stimson, G.V., des Jarlais, D., Gossop, M., & Strang, J. (1994). Methadone maintenance treatment in opiate dependence: A review. British Medical Journal, 309, 997–1000.
   PubMed Web of Science ®Google Scholar
• Fischer, B., Rehm, J., Kim, G., & Kirst, M. (2005). Eyes wide shut?—A conceptual and empirical critique of methadone maintenance treatment. European Addiction Research, 11(1), 1–14.
   PubMed Web of Science ®Google Scholar
• Freye, E. & Levy, J. (2000). Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram®): A case study. European Journal of Pain, 4(3), 307–311.
   PubMed Web of Science ®Google Scholar
• Gearing, F.R. & Schweitzer, M.D. (1974). An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. American Journal of Epidemiology, 100(2), 101–112.
   PubMed Web of Science ®Google Scholar
• Goldman, D., Oroszi, G., & Ducci, F. (2006). The genetics of addiction: Uncovering the genes. FOCUS: The Journal of Lifelong Learning in Psychiatry, iv(3), 401–415.
   Google Scholar
• Goldstein, A. & Judson, B.A. (1973). Proceedings: Efficacy and side effects of three widely different methadone doses. Proceedings of the National Conference on Methadone Treatment, 1, 21–44.
   PubMedGoogle Scholar
• Gordon, A.J. (2008). Case and commentary: Dependence vs. pain. Morbidity & Mortality Rounds on the Web. Retrieved April 3, 2009 from http://www.webmm.ahrq.gov/case.aspx?caseID=179
   Google Scholar
• Gossop, M. (2006). Methadone: Is it enough? Heroin Addiction and Related Clinical Problems, 8(4), 53–64.
   Google Scholar
• Green, M., Kellogg, S., & Kreek, M.J. (2004). Methadone: History, pharmacology, neurobiology, and use. Encyclopedia of Neuroscience (3rd ed.). Edinburgh: Elsevier. Retrieved June 5, 2009 from http://dualdisorder.org/assets/enc%20of%20neuroscience%20-%20methadone.pdf
   Google Scholar
• Hallinen, R., Ray, J., Byrne, A., Agho, K., & Attia, J. (2006). Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis. Drug & Alcohol Dependence, 81(2), 129–136.
   PubMed Web of Science ®Google Scholar
• Hiltunen, A.J., Beck, O., Hjemdahl, P., Liljeberg, P., Almstrom, U., Brodin, K.,von Wachenfeldt, J., & Borg, S. (1999). Rated well-being in relation to plasma concentrations of l- and d-methadone in satisfied and dissatisfied patients on methadone maintenance treatment. Psychopharmacology (Berlin), 143(4), 385–393.
   PubMed Web of Science ®Google Scholar
• Howell, E. (2008, July). Clinical aspects of addiction. Presentation at the University of Utah School on Alcoholism and Other Drug Dependencies, Physician Section. Salt Lake City, Utah.
   Google Scholar
• Inturrisi, C.E. & Verebely, K. (1972). The levels of methadone in the plasma in methadone maintenance. Clinical Pharmacology and Therapeutics, 3(5, part 1), 633–637.
   Google Scholar
• Jaffe, J.H. & O’Keeffe, C. (2003). From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug and Alcohol Dependence, 70(2 supp), S3–S11.
   Google Scholar
• Johnson, R.E., Chutuape, M.A., Strain, E.C., Walsh, S.L., Stitzer, M.L., & Bigelow, G.E. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. The New England Journal of Medicine, 343(18), 1290–1297.
   PubMed Web of Science ®Google Scholar
• Johnson, R.E., Jaffe, J.H., & Fudala, P.J. (1992). A controlled trial of buprenorphine treatment for opioid dependence. JAMA: The Journal of the American Medical Association, 267(20), 2750–2755.
   PubMed Web of Science ®Google Scholar
• Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone maintenance treatment (MMT): A review of historical and clinical issues. The Mount Sinai Journal of Medicine, 67(5 & 6), 347–364.
   PubMedGoogle Scholar
• Kleber, H.D. (2008). Methadone maintenance 4 decades later: Thousands of lives saved, but still controversial. JAMA: The Journal of the American Medical Association, 300(19), 2303–2305.
   PubMed Web of Science ®Google Scholar
• Kosten, T.R., Schottenfeld, R., Ziedonis, D., & Falcioni, J. (1993). Buprenorphine versus methadone maintenance for opioid dependence. The Journal of Nervous and Mental Disease, 181(6), 358–364.
   PubMed Web of Science ®Google Scholar
• Kreek, M.J. (1986). Tolerance and dependence: Implications for the pharmacological treatment of addiction. In Harris, L.S. (Ed): Problems of Drug Dependence: Proceedings of the 48^th Annual Scientific Meeting of the Committee on Problems of Drug Dependence, DHHS publication No. (ADM) 87–1508. Rockville, MD, NIDA, US Department of Health and Human Services, 53–62.
   Google Scholar
• Kreek, M.J. (1992). Rationale for maintenance pharmacotherapy of opiate dependence. Research Publications—Association for Research in Nervous and Mental Disease, 70, 205–230.
   PubMedGoogle Scholar
• Kreek, M.J., LaForge, K.S., & Butelman, E. (2002). Pharmacotherapy of addictions. Nature Reviews: Drug Discovery, 1, 710–726.
   PubMed Web of Science ®Google Scholar
• Layson-Wolf, C., Goode, J.V., & Small, R.E. (2002). Clinical use of methadone. Journal of Pain and Palliative Care Pharmacotherapy, 16(1), 29–59.
   PubMedGoogle Scholar
• Leavitt, S.B. (2001a). Practitioner panel: Methadone and heart health. Addiction Treatment Forum, X(3). Retrieved May 5, 2009 from http://www.atforum.com/SiteRoot/pages/current_pastissues/summer2001.shtml
   Google Scholar
• Leavitt, S.B. (2001b). Clinical concepts—Overcoming obstacles to optimum methadone dose. Addiction Treatment Forum, X(3). Retrieved May 5, 2009 from http://www.atforum.com/SiteRoot/pages/current_pastissues/summer2001.shtml
   Google Scholar
• Leavitt, S.B. (2003). Methadone dosing & safety in the treatment of opioid addiction. Addiction Treatment Forum, September, 1–8.
   Google Scholar
• Leavitt, S.B., Shinderman, M., Maxwell, S., Eap, C.B, & Paris, P. (2000). When “enough” is not enough: new perspectives on optimal methadone maintenance dose. Mt. Sinai Journal of Medicine, 67(5–6), 404–411.
   PubMedGoogle Scholar
• Li, Y., Kantelip, J.P., Gerritsen-van Schieveen, P., & Davani, S. (2008). Interindividual variability of methadone response: Impact of genetic polymorphism. Molecular Diagnosis & Therapy, 12(2), 109–124.
   PubMed Web of Science ®Google Scholar
• Ling, W., Charuvastra, C., Kaim, S.C., & Klett, C.J. (1976). Methadyl acetate and methadone as maintenance treatments for heroin addicts: A veterans administration cooperative study. Archives of General Psychiatry, 33(6), 709–720.
   PubMed Web of Science ®Google Scholar
• Ling, W., Wesson, D.R., Charuvastra, C., & Klett, C.J. (1996). A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry, 53(5), 401–407.
   PubMed Web of Science ®Google Scholar
• Loimer, N. & Schmid, R. (1992). The use of plasma levels to optimize methadone maintenance treatment. Drug and Alcohol Dependence, 30(3), 241–246.
   PubMed Web of Science ®Google Scholar
• Maremmani, I., Pacini, M., Lubrano, S., Lovrecic, M., & Perugi, G. (2003). Dual diagnosis heroin addicts. The clinical and therapeutic aspects. Heroin Addiction & Related Clinical Problems, 5(2), 7–98.
   Google Scholar
• Maremmani, I., Pacini, M., Lubrano S., Perugi G., Tagliamonte, A., Pani, P.P., Gerra, G., & Shinderman, M. (2008). Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV Axis 1 psychiatric comorbidity (Dual Diagnosis). European Addiction Research, 14, 134–142.
   PubMed Web of Science ®Google Scholar
• Maxwell, S. & Shinderman, M. (1999). Optimizing response to methadone maintenance treatment: Use of higher-dose methadone. Journal of Psychoactive Drugs, 31(2), 95–102.
   PubMed Web of Science ®Google Scholar
• Maxwell, S. & Shinderman, M.S. (2002). Optimizing long-term response to methadone maintenance treatment: A 152-week follow-up using higher-dose methadone. Journal of Addictive Diseases, 21(3), 1–12.
   PubMed Web of Science ®Google Scholar
• McLellan, A.T., Lewis, D.C., O’Brien, C.P., & Kleber, H.D. (2000). Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA:The Journal of the American Medical Association, 284, 1689–1695.
   PubMed Web of Science ®Google Scholar
• Moolchan, E.T., Umbricht, A., & Epstein, D. (2001). Therapeutic drug monitoring in methadone maintenance: Choosing a matrix. Journal of Addictive Diseases, 20(2), 55–73.
   PubMed Web of Science ®Google Scholar
• Moryl, N., Coyle, N., & Foley, K.M. (2008). Managing an acute pain crisis in a patient with advanced cancer: “This is as much of a crisis as a code.” JAMA: The Journal of the American Medical Association, 299(12), 1457–1467.
   PubMed Web of Science ®Google Scholar
• Newman, R.G. & Whitehill, W.B. (1979). Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. The Lancet, 2, 485–488.
   PubMed Web of Science ®Google Scholar
• Parrino, M.W. (2009). History of methadone maintenance treatment in the United States: Current challenges and initiatives. Addiction Professional, 7(2), N3–N6.
   Google Scholar
• Payte, J.T. (1991). A brief history of methadone in the treatment of opioid dependence: A personal perspective. Journal of Psychoactive Drugs, 23(2), 103–107.
   PubMed Web of Science ®Google Scholar
• Payte, J.T. & Khouri, E.T. (1993). Principles of Methadone Dose Determination. CSAT Treatment Improvement Protocol (TIP) Series, Volume 1; 1993. Out of print.
   Google Scholar
• Peles, E., Schreiber, S., Gordon, J., & Adelson, M. (2005). Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain, 113, 340–346.
   PubMed Web of Science ®Google Scholar
• Portenoy, R.K. (1996a). Opioid therapy for chronic nonmalignant pain: A review of the critical issues. Journal of Pain and Symptom Management, 11(4), 203–217.
   PubMed Web of Science ®Google Scholar
• Portenoy, R.K. (1996b). Opioid therapy for chronic nonmalignant pain: Clinicians’ perspective. Journal of Law, Medicine & Ethics, 24, 296–309.
   PubMed Web of Science ®Google Scholar
• Preston, K.L., Umbricht, A., & Epstein, D.H. (2000). Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry, 57(4), 395–404.
   PubMed Web of Science ®Google Scholar
• Rettig, R.A. & Yarmolinsky, A. (1995). Federal Regulation of Methadone Treatment. National Academy Press, Washington, D.C.
   Google Scholar
• Robert Wood Johnson Foundation. (2003). Dr. C. Everett Koop to lead discussion of the nation's most pressing substance abuse science and policy issues. News Release, February 10, 2003. Retrieved November 27, 2008 from http://www.rwjf.org/pr/product.jsp?id=21682
   Google Scholar
• Rosenblum, A., Joseph, H., Fong, C., Kipnis, S., Cleland, C., & Portenoy, R. (2003). Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA: The Journal of the American Medical Association, 289(18), 2370–2378.
   PubMed Web of Science ®Google Scholar
• Schottenfeld, R.S., Pakes, J.R., Oliveto, A., Ziedonis, D., & Kosten, T.R. (1997). Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry, 54(8), 713–720.
   PubMed Web of Science ®Google Scholar
• Shinderman, M. (2003, April). When enough is not enough: Research and practice supporting prescription of clinically effective doses in excess of 100 mg in methadone maintenance treatment. Presentation at the AATOD Conference, EUROPAD Section, Washington, DC. Retrieved December 4, 2008 from http://capqualitycare.com/articles.htm
   Google Scholar
• Siassi, I., Angle, B.P., & Alston, D.C. (1977). Maintenance dosage as a critical factor in methadone maintenance treatment. Addiction, 72(3), 261–268.
   Web of Science ®Google Scholar
• Sim, S.K. (1973). Methadone. Canadian Medical Association Journal, 109, 615–619.
   PubMed Web of Science ®Google Scholar
• Strain, E.C., Bigelow, G.E., Liebson, I.A., & Stitzer, M.L. (1999). Moderate- vs high-dose methadone in the treatment of opioid dependence: A randomized trial. JAMA: The Journal of the American Medical Association, 281(11), 1000–1005.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment (SAMHSA). (1995). Pregnant, substance-using women. Treatment Improvement Protocol (TIP) Series, 2. DHHS Publication No. (SMA) 95–3056. Rockville, MD: U.S. Retrieved November 18, 2008 from http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.chapter.22442
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. (2008). National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on Substance Abuse Treatment Facilities, DASIS Series: S-44, DHHS Publication No. (SMA) 08–4348, Rockville, MD. Retrieved December 6, 2008 from http://atforum.com/addiction-resources/documents/nssats2k7web.pdf
   Google Scholar
• Tennant, F.S. (1987). Inadequate plasma concentrations in some high-dose methadone maintenance patients. American Journal of Psychiatry, 144, 1349–1350.
   PubMed Web of Science ®Google Scholar
• Tenore, P.L. (2003). Guidance on optimal methadone dosing. Addiction Treatment Forum, 12(3), 1, 6–7.
   Google Scholar
• Uhl, G.R., Drgon, T., Johnson, C., Li, C.Y., Contoreggi, C., Hess, J., Naiman, D. & Liu, Q.R. (2008). Molecular genetics of addiction and related heritable phenotypes. Annals of the New York Academy of Sciences, 1141, 318–381
   PubMed Web of Science ®Google Scholar
• United States General Accounting Office (GAO). (1990). Report to the Chairman, Select Committee on Narcotics Abuse and Control, House of Representatives. Methadone maintenance: Some treatment programs are not effective; Greater federal oversight needed. GAO/HRD-90–104.
   Google Scholar
• Vazquez, V., Gury, C., & Laqueille, X. (2006). Methadone: From pharmacokinetic profile to clinical pharmacology. Encephale, 32(4 Pt 1), 478–486.
   PubMed Web of Science ®Google Scholar
• Wesson, D.R. & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259.
   PubMed Web of Science ®Google Scholar